SoftBank and PICC Capital led a $315m Series C round in XtalPi, an artificial intelligence-enabled drug research and development startup, with participation from Sequoia Capital, Tencent, CITIC Capital Partners, Mirae Asset Global Investments, FourSquare Capital, Parkway Life REIT, SIG China, Shunwei Capital, 5Y Capital, PICC Capital, CMB International, China Life Chengda, Oceanpine Capital, IMO Ventures, CICC Capital and SoftBank. "In the past few years, we have focused on developing and validating our platform's capabilities by working with some of the top innovative pharmaceutical and biotech companies in the world. As an advocate and trailblazer in AI drug discovery, our investors and we are heartened by several of our AI drug discovery collaborations that reached milestones in significantly shortened timeframes," Shuhao Wen, XtalPi Chairman and Co-Founder.